An updated edition of the July 20, 2026, article.
Genomics is a comprehensive study of genomes (an organism’s complete set of deoxyribonucleic acid or DNA). Recent scientific advances in this area have heightened interest from pharmaceutical and biotechnology companies seeking deeper insight into disease biology and more effective therapeutic strategies.
A key point to note is the difference between genetics and genomics. While genetics focuses on individual genes, genomics primarily aims to characterize all the genes of an organism. Genomics involves understanding how they interact with one another and with environmental factors to influence biological processes.
Insights from genomic research are increasingly being used to evaluate how patients respond to specific drugs. These findings are also driving the development of precise, more targeted treatments, contributing to the advancement of personalized medicine. As demand for innovative therapies continues to grow, genomics is poised to play an increasingly central role in the future of healthcare, despite the complexity inherent in genome-scale research.
The expanding genomics landscape has also supported the growth of synthetic biology, which applies engineering principles to biology. This emerging field involves redesigning organisms for diverse applications, including drug discovery, disease detection, enzyme engineering, gene editing and foundational research.
The rapid progress in the novel space of genomics has been fueled by steep declines in the cost, time, and effort needed to sequence an individual’s genome. A major player in this field is Illumina ILMN, a global leader in sequencing and array-based solutions for genetic and genomic analysis.
Diagnostic companies are using genomic sequencing data to identify genetic variations and connect them to known diseases. In contrast, other companies apply sequencing technologies to develop solutions across healthcare and other industries.
Another major advancement in the field is the emergence of genome-editing technologies, most notably CRISPR/Cas9. Companies specializing in gene editing, such as CRISPR Therapeutics AG CRSP and Beam Therapeutics, Inc. BEAM, are exploring these tools to potentially treat or even cure diseases caused by genetic mutations. As the name implies, these technologies enable precise modifications to an organism’s DNA, allowing scientists to correct harmful defects at their source.
According to Fortune Business Insights, the global genomics market was valued at $34.23 billion in 2025 and is expected to expand from $38.24 billion in 2026 to $99.26 billion by 2034, reflecting a compound annual growth rate (CAGR) of 12.66% over the period.
Per a Grandview Research article, the global synthetic biology market size was valued at $18.9 billion in 2025 and is projected to reach $69.2 billion by 2033, at a CAGR of 17.7% from 2026 to 2033.
If you're looking to capitalize on this trend, our Genomics and Synthetic Biology screen makes it easy to identify high-potential stocks at any given time. At present, stocks such as GENEDX HOLDINGS WGS, NeoGenomics NEO and Intellia Therapeutics NTLA hold potential.
Explore 40 cutting-edge investment themes with Zacks Thematic Investing Screens and uncover your next big opportunity.
3 Genomics Stocks to Consider
GeneDx Holdings is a leading player in rare disease diagnostics, focused on advancing genomic insights to improve patient outcomes. The company leverages deep clinical expertise, proprietary technology and its expansive GeneDx Infinity dataset — one of the largest rare disease genomic repositories globally — to support accurate and timely diagnoses.
Its core testing offerings, ExomeDx and GenomeDx, are highly regarded among clinicians and have received FDA Breakthrough Device Designation, underscoring their clinical utility and innovation. Beyond diagnostics, GeneDx is also positioning its dataset as a valuable asset for biopharma, enabling AI-driven discovery and development.
With more than 25 years of experience, over 4,800 genetic diseases diagnosed and a robust publication record, GeneDx is building a scalable genomics platform that could play a central role in the evolution of precision medicine.
WGS currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
NeoGenomics, Inc. is a leading provider of oncology diagnostic solutions that support precision medicine. The company operates a network of cancer-focused testing laboratories across the United States and the United Kingdom. It offers one of the most comprehensive oncology-focused testing menus spanning the cancer care continuum, serving oncologists, pathologists, hospital systems, academic medical centers and pharmaceutical companies. Its innovative diagnostic and predictive testing solutions provide timely, actionable insights that help guide personalized treatment and care decisions.
As of June 30, 2026, the company operated College of American Pathologists (“CAP”) accredited and Clinical Laboratory Improvement Amendments of 1988 (“CLIA”) certified laboratories in Fort Myers, FL; Aliso Viejo and Carlsbad, CA; Research Triangle Park, NC; Ramsey, NJ; and Houston, TX; and a CAP accredited full-service, sample-processing laboratory in Cambridge, United Kingdom. NEO also has several small, non-processing laboratory locations across the United States to provide analysis services.
Shares of the company have surged 47.7% in the year so far. NEO currently carries a Zacks Rank #2 (Buy).
Intellia Therapeutics leverages its proprietary technologies and expertise, including CRISPR-based gene-editing technologies, oligonucleotides and lipid nanoparticles (LNPs), to develop novel, first-in-class therapeutic candidates. Its leading programs include lonvoguran ziclumeran (lonvo-z, formerly NTLA-2002) for the treatment of hereditary angioedema (HAE) and nexiguran ziclumeran (nex-z, formerly NTLA-2001) for transthyretin (ATTR) amyloidosis.
These lead candidates represent the company’s most advanced programs and are the first in vivo genome-editing candidates to progress into phase III clinical development.
In April 2026, Intellia reported positive top-line results from the global phase III HAELO clinical trial evaluating lonvo-z in HAE.
Intellia expects the FDA to accept its biologics license application (BLA) seeking approval for lonvo-z in the second half of 2026. If approved, Intellia plans to launch lonvo-z commercially in the first half of 2027.
The company currently carries a Zacks Rank #3 (Hold).
Research Chief Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
NeoGenomics, Inc. (NEO): Free Stock Analysis Report
Intellia Therapeutics, Inc. (NTLA): Free Stock Analysis Report
GeneDx Holdings Corp. (WGS): Free Stock Analysis Report
Illumina, Inc. (ILMN): Free Stock Analysis Report
Beam Therapeutics Inc. (BEAM): Free Stock Analysis Report
CRISPR Therapeutics AG (CRSP): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).